Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
Summary
Edgewise Therapeutics reported positive top-line results from its 12-week Phase 2 CIRRUS-HCM study of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy. The company highlighted improvements in hemodynamics, biomarkers, symptoms, and functional status, along with a tolerability profile that showed no new safety signals and no meaningful LVEF reduction. Edgewise says the data support moving EDG-7500 into Phase 3, with initiation targeted for the fourth quarter of 2026. The release also positions the drug as a differentiated cardiac sarcomere modulator for a major unmet need in HCM treatment.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected